Policy SITC is committed to taking a big tent approach involving all critical stakeholders in moving the field forward towards finding a cure for cancer. The US federal government is one of these critical stakeholders and impacts every aspect of the field of immunotherapy from basic research, regulatory approval, clinical care, and beyond. The SITC Policy Committee and Subcommittees are tasked with fostering SITC’s engagement with the federal government and establishing the Policy strategic priorities for the Society
Abstract Embargo & Release Information Policy Below are the policies of the SITC abstract submission process
SITC shall meet all subrecipient FCOI requirements, as applicable. This policy is publicly posted on the SITC website...The statements below outline the policies and procedures concerning information gathering and dissemination practices for our organization
Media Policy For more information, please contact the SITC Communications Team at +1 414 271 2456 or communications@sitcancer.org. The following policies have been established for journalists covering the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2023) and exhibitors/public relations professionals wishing to distribute materials related to research presented at the meeting
SITC 2019 Annual Meeting: Session 300: SITC Policy Committee Update
The Policy and Advocacy Committee reviews and analyzes immunotherapy and oncology related policy issues to advise the Board of Directors on the broad policy, advocacy, regulatory and value priorities of the society
Purpose There is great interest among clinicians as well as regulatory authorities to address the lack of drug development for products intended specifically for use with radiation therapy. Emerging from the enthusiasm and momentum of a session at the AACR-sponsored Accelerating Anticaner...
02-22-2018 - 02-23-2018 Bethesda MD
Join
Renew
Member Directory
My Profile
Email Sign-up
Volunteer
Support SITC
Contact Us